Shaw Gary Y, Sechtem Philip, Searl Jeff, Dowdy Emily S
Voice and Swallowing Care Center, Research Medical Center, Kansas City, Missouri, USA.
Ann Otol Rhinol Laryngol. 2006 Apr;115(4):260-7. doi: 10.1177/000348940611500403.
Since its approval by the US Food and Drug Administration in 1997 for management of medically refractory seizures, more than 35,000 patients have been implanted with the Cyberonics vagal nerve stimulator. Preliminary reports described transient vocal changes in the majority of subjects, which were thought to be short-term. However, these reports were for the most part based upon perceptual evaluations by the subjects themselves. Later reports described possibly more permanent recurrent laryngeal nerve injury and recommended measuring the nerve diameter to use the safest spiral cuff electrode. To date, no study has systematically evaluated vocal fold mobility in subjects before and after implantation. The objectives of this study were to determine the true incidence of both short- and long-term recurrent laryngeal nerve injuries and determine whether there are any potential indicators to predict in which patients long-term nerve deficits may develop.
Thirteen subjects underwent preimplantation laryngeal electromyography, videolaryngoscopy, measurement of the maximum phonation time, Voice Handicap Index determination, and Consensus Auditory-Perceptual Evaluation of Voice. Two weeks after implantation, all subjects underwent videolaryngoscopy. Three months after implantation and activation of the device, all subjects were reevaluated.
Six of the 13 subjects had significant vocal fold mobility abnormalities at 2 weeks. Significant electromyographic abnormalities were detected before implantation in 5 subjects. All 5 of these subjects, at 3 months after implantation, had prolonged left vocal fold paresis.
The authors conclude that perioperative vocal fold paresis occurs in approximately 50% of subjects. Further, laryngeal electromyography performed before implantation of the vagal nerve stimulator is a statistically significant predictor (p < .05) of which patients may be at risk for extended vocal fold abnormalities. Possible explanations for this phenomenon are offered. Surgical modifications to limit vagal nerve injury are offered.
自1997年美国食品药品监督管理局批准其用于治疗药物难治性癫痫以来,已有超过35000名患者植入了赛博onics迷走神经刺激器。初步报告描述了大多数受试者出现短暂的声音变化,认为是短期的。然而,这些报告大多基于受试者自身的感知评估。后来的报告描述了可能更持久的喉返神经损伤,并建议测量神经直径以使用最安全的螺旋袖带电极。迄今为止,尚无研究系统评估植入前后受试者声带的活动度。本研究的目的是确定短期和长期喉返神经损伤的真实发生率,并确定是否有任何潜在指标可预测哪些患者可能出现长期神经功能缺损。
13名受试者在植入前接受了喉肌电图检查、视频喉镜检查、最大发声时间测量、嗓音障碍指数测定以及嗓音的共识听觉-感知评估。植入后两周,所有受试者均接受了视频喉镜检查。植入并激活设备三个月后,对所有受试者进行了重新评估。
13名受试者中有6名在两周时出现了明显的声带活动度异常。5名受试者在植入前检测到明显的肌电图异常。所有这5名受试者在植入后三个月时均出现左侧声带麻痹延长。
作者得出结论,围手术期声带麻痹在大约50%的受试者中发生。此外,在植入迷走神经刺激器之前进行的喉肌电图检查是一个具有统计学意义的预测指标(p <.05),可预测哪些患者可能有发生长期声带异常的风险。文中提供了对这一现象的可能解释。还提出了限制迷走神经损伤的手术改进方法。